Literature DB >> 13678228

Comparative efficacy of Keishi-bukuryo-gan and pentoxifylline on RBC deformability in patients with "oketsu" syndrome.

H Hikiami1, H Goto, N Sekiya, N Hattori, I Sakakibara, Y Shimada, K Terasawa.   

Abstract

Keishi-bukuryo-gan (Gui-Zhi-Fu-Ling-Wan) (KBG) is one of the prescriptions in Japanese traditional medicine for improving the "oketsu" syndrome, so-called blood stasis syndrome. "Oketsu" syndrome is an important pathological conception in Japanese traditional medicine and often accompanies cerebro-vascular disorders. Previously, we were able to reveal a deterioration of RBC (Red blood cell) deformability and viscoelasticity in patients with "oketsu" syndrome. The purpose of the present study was to evaluate whether KBG has an effect on RBC deformability in comparison with pentoxifylline (PXF). The subjects were 30 male patients with multiple lacunar infarctions. Eighteen patients (44-79 yrs, mean +/- SD, 66.1 +/- 10.7 yrs) were treated with 12 g of KBG daily for 4 weeks (KBG group). Twelve patients (59-78 yrs, 70.7 +/- 6.4 yrs) were treated with 300 mg of PXF daily for 4 weeks (PXF group). Based on the "oketsu" score, the patients of each group were divided into two subgroups, a non-"oketsu" group ("oketsu" score 20 points or less) and an "oketsu" group ("oketsu" score 21 points or higher). KBG had significant effects on RBC deformability as evaluated by filtration method. KBG also significantly increased intracellular ATP content, as did PXF. Moreover, KBG was more effective for patients with a more severe "oketsu" state. However, PXF was effective only in patients with "oketsu" syndrome, who might have deteriorated RBC deformability. In conclusion, the effect of KBG on RBC deformability was by no means inferior to PXF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13678228     DOI: 10.1078/094471103322331395

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  17 in total

Review 1.  What has been overlooked on study of Chinese materia medica in the West?

Authors:  Willow J H Liu
Journal:  Chin J Integr Med       Date:  2015-07-09       Impact factor: 1.978

2.  Examination of clinical efficacy of keishibukuryogan on non-specific complaints associated with varicose veins of the lower extremity.

Authors:  Shinobu Hayashi; Shintaro Shibutani; Hirotoki Okubo; Tatsuya Shimogawara; Tsuyoshi Ichinose; Yasuhiro Ito; Kouki Mihara; Tomohisa Egawa; Atsushi Nagashima; Hideaki Obara; Yuko Kitagawa
Journal:  Ann Vasc Dis       Date:  2014-07-30

3.  Current research and future directions in pattern identification: Results of an international symposium.

Authors:  Myeong Soo Lee; Ju Ah Lee; Terje Alraek; Zhao-Xiang Bian; Stephen Birch; Hirozo Goto; Jeeyoun Jung; Shung-Te Kao; Sang-Kwan Moon; Bongki Park; Kyung-Mo Park; Sooseong You; Kyung-Jin Yun; Chris Zaslawski
Journal:  Chin J Integr Med       Date:  2014-06-18       Impact factor: 1.978

4.  Effect of keishibukuryogan on endothelial function in patients with at least one component of the diagnostic criteria for metabolic syndrome: a controlled clinical trial with crossover design.

Authors:  Yutaka Nagata; Hirozo Goto; Hiroaki Hikiami; Tatsuya Nogami; Makoto Fujimoto; Naotoshi Shibahara; Yutaka Shimada
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-22       Impact factor: 2.629

5.  The traditional Japanese formula keishibukuryogan inhibits the production of inflammatory cytokines by dermal endothelial cells.

Authors:  Yoko Yoshihisa; Megumi Furuichi; Mati Ur Rehman; Chieko Ueda; Teruhiko Makino; Tadamichi Shimizu
Journal:  Mediators Inflamm       Date:  2010-12-28       Impact factor: 4.711

6.  Keishibukuryogan (gui-zhi-fu-ling-wan), a Kampo formula, decreases disease activity and soluble vascular adhesion molecule-1 in patients with rheumatoid arthritis.

Authors:  Kazuya Nozaki; Hiroaki Hikiami; Hirozo Goto; Takako Nakagawa; Naotoshi Shibahara; Yutaka Shimada
Journal:  Evid Based Complement Alternat Med       Date:  2006-09       Impact factor: 2.629

7.  Effectiveness of keishibukuryogan on chronic-stage lichenification associated with atopic dermatitis.

Authors:  Megumi Mizawa; Teruhiko Makino; Hiroaki Hikiami; Yutaka Shimada; Tadamichi Shimizu
Journal:  ISRN Dermatol       Date:  2012-11-14

8.  Keishibukuryogan reduces renal injury in the early stage of renal failure in the remnant kidney model.

Authors:  Takako Nakagawa; Izumi Tashiro; Makoto Fujimoto; Michiko Jo; Shinya Sakai; Hiroshi Oka; Hirozo Goto; Yutaka Shimada; Naotoshi Shibahara
Journal:  Evid Based Complement Alternat Med       Date:  2011-05-03       Impact factor: 2.629

9.  A Proteomic Approach for the Diagnosis of 'Oketsu' (blood stasis), a Pathophysiologic Concept of Japanese Traditional (Kampo) Medicine.

Authors:  Chinami Matsumoto; Tetsuko Kojima; Kazuo Ogawa; Satoshi Kamegai; Takuya Oyama; Yukari Shibagaki; Tetsuo Kawasaki; Hiroshi Fujinaga; Kozo Takahashi; Hiroaki Hikiami; Hirozo Goto; Chizuru Kiga; Keiichi Koizumi; Hiroaki Sakurai; Hiroshi Muramoto; Yutaka Shimada; Masahiro Yamamoto; Katsutoshi Terasawa; Shuichi Takeda; Ikuo Saiki
Journal:  Evid Based Complement Alternat Med       Date:  2007-06-15       Impact factor: 2.629

10.  An Alternative Approach to Atopic Dermatitis: Part I-Case-Series Presentation.

Authors:  Hiromi Kobayashi; Kuniaki Takahashi; Nobuyuki Mizuno; Haruo Kutsuna; Masamitsu Ishii
Journal:  Evid Based Complement Alternat Med       Date:  2004-06-01       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.